Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Total Current Liabilities
All obligations due within one year.
Helix BioPharma Corp.TSX: HBP.TO
Total Current Liabilities · Q3 FY2026 · quarter ended Apr 2026
Total current liabilities rises 179.0% from a year ago
Total current liabilities stood at CA$6.69M at the end of Q3 FY2026, up 179.0% from a year earlier and up 111.5% from the prior quarter. Over 3 fiscal years it compounded at -1.9% a year.
Context
- Total current liabilities amounted to 31.3% of total assets at the end of Q3 FY2026, down 206.5 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +179.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
CAD · from the balance sheet
- Latest · FY2025
- 3.22M CAD
- Year-over-year change
- +103.7%
- 4-year CAGR
- -4.5%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 3.22M | +103.7% |
| FY2024 | 2024-07-31 | 1.58M | -15.7% |
| FY2023 | 2023-07-31 | 1.87M | -45.1% |
| FY2022 | 2022-07-31 | 3.41M | -12.0% |
| FY2021 | 2021-07-31 | 3.87M | — |
Total Current Liabilities vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +179.0% is the highest of 5, against a peer median of +6.5%.
- Total current liabilities amounts to 31.3% of total assets for HBP.TO, versus a peer median of 22.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $28.84M USD | +21.0% | -5.8% | 22.0% | |
| Apr 2026 | CA$10.94M CAD | -53.1% | +73.6% | 713.4% | |
| Mar 2026 | CA$7.13M CAD | -8.1% | -16.8% | 22.7% | |
| Apr 2026 | CA$6.69M CAD | +179.0% | -1.9% | 31.3% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $4.57M USD | +69.2% | +13.1% | 6.1% |
| Peer median (excluding HBP.TO) | — | +6.5% | +3.7% | 22.3% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.